【新唐人2013年12月25日讯】中国大陆传出新生儿接种B肝疫苗后死亡，目前已知有8名婴儿在注射问题疫苗之后，发生异常反应而死亡。深圳市疾病预防控制中心23号才通报，全面停用某公司的乙肝疫苗。外界质疑，为什么要等到悲剧发生后，有关部门才对“疑似问题疫苗”全面叫停？而且仅仅只是通报“一停了之”，完全忽视民众对“问题疫苗”的知情权。民众质疑，难道这其中还隐藏什么不为人知的猫腻？
连日来，湖南、四川、广东多地发生婴儿接种乙肝疫苗后死亡事件，引发公众对疫苗安全性的担忧。
广东省疾控中心证实，深圳一名新生婴儿12月17号接种乙肝疫苗68分钟后死亡。11月以来，广东先后发生了4例疑似接种乙肝疫苗后死亡的病历。此外，湖南、四川等地也先后出现新生儿在接种乙肝疫苗后死亡案例。
12月21号，四川眉山居民高兵之子在眉山“中铁医院”出生，隔天接种乙肝疫苗，10多个小时后死亡。高兵及家属怀疑，孩子死亡疑似与接种乙肝疫苗有关。
据了解，这些问题疫苗是由深圳“康泰公司”生产，这家公司所制造的乙肝疫苗，市场占有率高达50%以上，然而相对的应变措施却如此迟缓。
23号下午，深圳市药品监督管理局通报，深 圳“康泰生物制品股份有限公司”生产的重组乙肝疫苗，在库成品已全部暂停销售及发运工作，在有效期内的重组乙肝疫苗各规格已销售186批次，合计35,891,194支。但通告并没有说明已销售疫苗的使用和流向情况。
民间公益团体“食品药品安全宣导联盟”成员姬来松律师表示，这件事情发生在中国，一点都不觉得吃惊。
河南律师姬来松：“出现这个事情，让我们想起几年前的三鹿奶粉事件，我觉得这个事情的发生和当初的三鹿奶粉其实是一样的，还是监管不力，食品安全和药品安全的机构都是不作为，或者是乱作为，这是导致这次事件发生的最根本的原因。”
山西疫苗受害家长易文龙表示，卫生部门打击力度不够，所以造成越来越多有关疫苗品质异常反应的问题。
山西疫苗受害家长易文龙：“我们是普通老百姓，我们也没有能力去调查到底有多少例，但据我知道我们全村有几百例吧，这个疫苗造假，不单纯的是报导的假疫苗，这个疫苗发生异常反应，这就是厂家赔钱，这就涉及到官商勾结的问题，卫生部门说，他不可能因为这些少数的家长而影响大众的接受 疫苗，他不敢承认的意思，怕引起接受疫苗的恐慌。”
按照规定，疫苗产品上市销售前，必须通过“中国食品药品检定研究院”的检验，并获得生物制品批签发合格证。根据媒体报导，深圳“康泰生物”出事的重组乙肝疫苗，都按规定获得了合格证。但尽管通过检验，还是出了问题。
据了解，“康泰生物”并不是第一次出事。2010年，广东揭阳市惠来县46名学生接种“康泰生物”公司生产的乙肝疫苗后，曾出现头晕、恶心、全身无力等症状而住院治疗，但当时的广东省卫生部门表示，那批疫苗没有问题。最后也是不了了之。
姬来松：“我认为最主要的还是体制问题，一个不受监督的体制、不受监督的权力，他肯定就是为所欲为，他根本不把人民的生命健康放在眼里，只要他们维护他的体制、维护他的利益，那这些东西他就可以忽略。”
姬来松表示，对于注射问题疫苗造成多起婴幼儿死亡事件，卫生部门不能随便找一个替罪羊来顶替，把深层次的问题给掩盖，如果不公布问题疫苗的流向和原因，那么这绝对不是第一例，也不是最后一例，中国民众的生命安全堪虑。
采访/常春 编辑/黄亿美 后制/郭敬
Chinese concerned over unclear information on problem hepatitis B vaccines
Another newborn baby recently died from a hepatitis B vaccine
in mainland China, while seven babies in three provinces also
had abnormal reactions and died after getting the same vaccine.
On Dec. 23, the Shenzhen Center for Disease Control and
Prevention issued a notice banning the vaccine.
Many are questioning why the health department
did not recall the vaccines until accidents happened.
The notice to ban the vaccine did not explain
where the questioned vaccines have gone to.
People’s rights to know have been
completely ignored by the authorities.
People questioned whether there is something being hidden.
In the past few days, babies in Hunan, Sichuan and Guangdong
provinces have been dying from hepatitis B vaccinations,
triggering public concerns about vaccine safety.
The Guangdong Center for Disease Control confirmed that a
newborn baby in Shenzhen died an hour after receiving the
hepatitis B vaccine on Dec. 17.
Since November, four babies in Guangdong province are
suspected to have died from the hepatitis B vaccination.
Newborn deaths after hepatitis B vaccination
has also appeared in Hunan, Sichuan and other regions.
On Dec. 21, the son of Gao Bing, a Meishan City resident in
Sichuan province, was born in Meishan Railway Hospital
and died 10 hours after hepatitis B vaccination.
Gao Bing and his family suspect the baby’s death
was related to the hepatitis B vaccine.
The vaccine is reportedly produced
by the Shenzhen-based company Biokangtai.
Their hepatitis B vaccine has an over 50% market share, but
relatively slow contingency measures.
On Dec. 23, the Shenzhen Drug Administration reported that
the recombinant hepatitis B vaccines produced by Biokangtai
have been suspended from selling and shipping.
Up until then, nearly 200 batches of the vaccine
have been sold, totaling nearly 36 million doses.
But the notice did not specify how the vaccines have been used
and where the vaccines were sold to.
Non-profit group “food and drug safety advocacy coalition"
lawyer Ji Laisong says such things are not surprising in China.
Ji Laisong, Henan lawyer: “The hepatitis B vaccine incident
reminds me of the Sanlu milk powder scandal a few years ago.
I believe this case and Sanlu milk powder case
are all due to lack of supervision.
The primary reason is because food safety and
pharmaceutical safety agencies do not act, or act disorderly."
Shanxi resident Yi Wenlong, who’s child was a victim, says
the series of abnormal reactions from the vaccine results from
the health department’s inadequate crackdown on such issues.
Yi Wenlong, Shanxi resident and parent of vaccine victim:
“We ordinary people do not have the ability to investigate.
As I know there are hundreds of victim’s cases in our village.
The counterfeit vaccine wasn’t simply reported as such,
but as an abnormal reaction from the vaccine.
Since the manufacturers will lose money,
it relates to the issue of collusion.
The health department will not impact majority infants’
vaccination because of the minority parents.
They dare not admit it for fear of people refusing the vaccine."
According to regulations, before being released, vaccine
products must pass “Chinese Academy of Food and Drug
Adiministration" tests and get certification to release batches
of biological products.
Media reports say the recombinant hepatitis B vaccine
from Biokangtai obtained the certificate and
passed the inspection, yet still had problems.
This was not the first accident for Biokangtai.
In 2010, after 46 students in Guangdong’s Huilai County
were hospitalized due to dizziness, nausea, and weakness after
receiving Biokangtai’s hepatitis B vaccine.
But the Guangdong Provincial Health Department said
the batches of the vaccine had no problem
and left the issue unresolved.
Ji Laisong: “I think the main problem is still the system.
Under an unmonitored system, they certainly do as they please
and ignore people’s wellbeing with unsupervised power, as
long as they maintain that system
they can safeguard their interests."
Ji Laisong says the health department can’t just find a scapegoat
to hide deep-rooted problems for so many infant deaths caused
by the vaccine injection.
This is definitely not the first case, nor the last if information
isn’t released on how the vaccines were used and the cause of
the problem. This is a big safety concern for people in China.
Interview/ChangChun Edit/HuangYimei Post-Production/GuoJing
